HRP20201323T1 - Protutijela koja se specifično vežu na tl1a - Google Patents
Protutijela koja se specifično vežu na tl1a Download PDFInfo
- Publication number
- HRP20201323T1 HRP20201323T1 HRP20201323TT HRP20201323T HRP20201323T1 HR P20201323 T1 HRP20201323 T1 HR P20201323T1 HR P20201323T T HRP20201323T T HR P20201323TT HR P20201323 T HRP20201323 T HR P20201323T HR P20201323 T1 HRP20201323 T1 HR P20201323T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody according
- heavy chain
- tl1a
- recombinant antibody
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (13)
1. Rekombinantno protutijelo koje se specifično veže na TNF-sličan ligand 1A (TL1A) i sadrži varijabilnu regiju teškog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 3 i varijabilnu regiju lakog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 4.
2. Rekombinantno protutijelo prema patentnom zahtjevu 1, naznačeno time što protutijelo sadrži konstantnu regiju ljudskog IgG1 teškog lanca, proizvoljno pri čemu konstantna regija ljudskog IgG1 teškog lanca sadrži SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, ili SEQ ID NO: 66.
3. Rekombinantno protutijelo prema patentnom zahtjevu 1, naznačeno time što protutijelo sadrži konstantnu regiju ljudskog IgG4 teškog lanca, proizvoljno pri čemu konstantna regija ljudskog IgG4 teškog lanca sadrži SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, ili SEQ ID NO: 69.
4. Rekombinantno protutijelo prema patentnom zahtjevu 1, naznačeno time što protutijelo sadrži konstantnu regiju ljudskog IgG2 teškog lanca, proizvoljno pri čemu konstantna regija ljudskog IgG2 teškog lanca sadrži SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 70, ili SEQ ID NO: 71.
5. Rekombinantno protutijelo prema patentnom zahtjevu 1, naznačeno time što protutijelo sadrži lambda konstantnu regiju ljudskog lakog lanca.
6. Rekombinantno protutijelo prema patentnom zahtjevu 5, naznačeno time što rekombinantno protutijelo obuhvaća lagani lanac koji sadrži sekvencu aminokiseline SEQ ID NO: 61.
7. Rekombinantno protutijelo prema patentnom zahtjevu 2 ili 6, naznačeno time što rekombinantno protutijelo obuhvaća teški lanac koji sadrži sekvencu aminokiseline SEQ ID NO: 60.
8. Pripravak, naznačen time što sadrži rekombinantno protutijelo prema bilo kojem od patentnih zahtjeva 1-7 i farmaceutski prihvatljiv nosač.
9. Rekombinantno protutijelo prema bilo kojem od patentnih zahtjeva 1-7, naznačeno time što je za uporabu za bolesti dišnih puteva, astme, KOPB, plućne sarkoidoze, alergijskog rinitisa, plućne fibroze, cistične fibroze, gastrointenstinalne bolesti, upalne bolesti crijeva, kolitisa, ulceroznog kolitisa, eozinofilnog ezofagitisa, gastrointestinalne bolesti povezane s cističnom fibrozom, sindroma iritabilnog crijeva, Crohnove bolesti, artritisa, reumatoidnog artritisa, kožne bolesti, atopijskog dermatitisa, ekcema, ili sklerodermije.
10. Rekombinantno protutijelo prema bilo kojem od patentnih zahtjeva 1-7, naznačeno time što je za uporabu za liječenje astme.
11. In vitro postupak za otkrivanje TL1A (i) na površini mononuklearnih stanica periferne krvi (PBMC), pri čemu obuhvaća dovođenje u kontakt protutijela prema bilo kojem od zahtjeva 1-7 s mononuklearnim stanicama periferne krvi izoliranim od subjekta, otkrivanje protutijela vezanog za TL1A na površini mononuklearnih stanica periferne krvi i, proizvoljno, kvantificiranje razine TL1A na mononuklearnim stanicama periferne krvi, (ii) u krvnom serumu, koji obuhvaća dovođenje u kontakt protutijela prema bilo kojem od patentnih zahtjeva 1-7 s krvnim serumom dobivenim od subjekta, otkrivanje protutijela vezanog za TL1A u serumu i, proizvoljno, kvantificiranje razine TL1A u krvnom serumu ili (iii) u uzorku tkiva izoliranom iz subjekta, koji obuhvaća dovođenje u kontakt protutijela prema bilo kojem od patentnih zahtjeva 1-7 s tkivom izoliranim iz subjekta da nastane kompleks protutijelo-TL1A, i otkrivanje kompleksa u tkivu.
12. Transformirana stanica naznačena time što eksprimira protutijelo prema bilo kojem od patentnih zahtjeva 1-7.
13. Polinukleotid koji ima sekvencu nukleinske kiseline koja kodira protutijelo prema patentnom zahtjevu 1, koji sadrži varijabilnu regiju teškog lanca koja sadrži sekvencu aminokiseline SEQ ID NO: 3 i drugu sekvencu nukleinske kiseline koja kodira varijabilnu regiju lakog lanca protutijela koja sadrži sekvencu aminokiseline SEQ ID NO: 4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220442P | 2015-09-18 | 2015-09-18 | |
| EP16774750.0A EP3350223B1 (en) | 2015-09-18 | 2016-09-16 | Antibodies that specifically bind to tl1a |
| PCT/US2016/052040 WO2017049024A1 (en) | 2015-09-18 | 2016-09-16 | Antibodies that specifically bind to tl1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201323T1 true HRP20201323T1 (hr) | 2020-11-27 |
Family
ID=57043002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201323TT HRP20201323T1 (hr) | 2015-09-18 | 2020-08-25 | Protutijela koja se specifično vežu na tl1a |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US10138296B2 (hr) |
| EP (2) | EP3350223B1 (hr) |
| JP (2) | JP7013366B2 (hr) |
| KR (1) | KR101998535B1 (hr) |
| CN (1) | CN108137693B (hr) |
| AR (1) | AR106055A1 (hr) |
| AU (2) | AU2016323460B2 (hr) |
| BR (2) | BR112018005407A8 (hr) |
| CA (1) | CA2997015A1 (hr) |
| CL (1) | CL2018000711A1 (hr) |
| CO (1) | CO2018003736A2 (hr) |
| CY (1) | CY1123499T1 (hr) |
| DK (1) | DK3350223T3 (hr) |
| EA (1) | EA201890756A1 (hr) |
| ES (1) | ES2810751T3 (hr) |
| HK (2) | HK1251002A1 (hr) |
| HR (1) | HRP20201323T1 (hr) |
| HU (1) | HUE051496T2 (hr) |
| IL (1) | IL257761B2 (hr) |
| LT (1) | LT3350223T (hr) |
| MA (2) | MA52643A (hr) |
| MD (1) | MD3350223T2 (hr) |
| MX (1) | MX2018003185A (hr) |
| PE (1) | PE20181080A1 (hr) |
| PH (1) | PH12018500580A1 (hr) |
| PL (1) | PL3350223T3 (hr) |
| PT (1) | PT3350223T (hr) |
| RS (1) | RS60703B1 (hr) |
| SI (1) | SI3350223T1 (hr) |
| TW (1) | TWI703158B (hr) |
| UA (1) | UA125284C2 (hr) |
| WO (1) | WO2017049024A1 (hr) |
| ZA (1) | ZA201801427B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| BR122020013379B1 (pt) | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| EP2978440B1 (en) | 2013-03-27 | 2019-10-02 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra |
| US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| AU2016364992B2 (en) * | 2015-12-04 | 2021-12-09 | University Of Iowa Research Foundation | Apparatus, systems and methods for predicting, screening and monitoring of encephalopathy / delirium |
| EP3430172A4 (en) | 2016-03-17 | 2019-08-21 | Cedars-Sinai Medical Center | METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2 |
| US10322174B2 (en) | 2016-10-26 | 2019-06-18 | Cedars-Sinai Medical Center | Neutralizing anti-TL1A monoclonal antibodies |
| EP3784699A4 (en) | 2018-04-25 | 2022-04-13 | Prometheus Biosciences, Inc. | OPTIMIZED ANTI-TL1A ANTIBODIES |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| WO2024026386A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibody formulations |
| WO2024026395A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| CN1237076C (zh) | 1999-01-15 | 2006-01-18 | 杰南技术公司 | 具有改变的效应功能的多肽变体 |
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2536086C (en) | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| CA2560742A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| US20090317388A1 (en) | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
| DK1919954T3 (en) | 2005-08-30 | 2017-01-30 | Univ Miami | Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins |
| WO2007076465A2 (en) | 2005-12-23 | 2007-07-05 | Diadexus, Inc. | Cln248 antibody compositions and methods of use |
| US20110217310A1 (en) | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| WO2008106451A2 (en) | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| CA2705292C (en) | 2007-11-13 | 2016-06-21 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against tl1a |
| WO2010118210A1 (en) | 2009-04-08 | 2010-10-14 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
| WO2011080314A2 (en) | 2009-12-31 | 2011-07-07 | Deutsches Krebsforschungszentrum | Novel modulators of trail signalling |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| MX2013013329A (es) | 2011-05-20 | 2014-04-16 | Us Government | Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos. |
| BR122020013379B1 (pt) | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| AP2015008605A0 (en) * | 2013-01-02 | 2015-07-31 | Glenmark Pharmaceuticals Sa | Antibodies that bind to tl1a and their uses |
| EP2978440B1 (en) | 2013-03-27 | 2019-10-02 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra |
| CN105307676A (zh) * | 2013-04-05 | 2016-02-03 | 豪夫迈·罗氏有限公司 | 抗il-4抗体和双特异性抗体及其用途 |
| US20160096885A1 (en) | 2013-05-17 | 2016-04-07 | Cedars-Sinal Medical Center | Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis |
| US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
| EP3041580A4 (en) | 2013-09-06 | 2017-05-03 | Cedars-Sinai Medical Center | Systems, devices and methods for anti-tl1a therapy |
| SG10201810298VA (en) | 2013-11-13 | 2018-12-28 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
| PT3283499T (pt) | 2015-04-15 | 2022-08-23 | Biosearch Tech Inc | Sondas de extintor dual |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
-
2016
- 2016-09-14 TW TW105130075A patent/TWI703158B/zh active
- 2016-09-16 DK DK16774750.0T patent/DK3350223T3/da active
- 2016-09-16 KR KR1020187007337A patent/KR101998535B1/ko active IP Right Grant
- 2016-09-16 HU HUE16774750A patent/HUE051496T2/hu unknown
- 2016-09-16 LT LTEP16774750.0T patent/LT3350223T/lt unknown
- 2016-09-16 SI SI201630885T patent/SI3350223T1/sl unknown
- 2016-09-16 EA EA201890756A patent/EA201890756A1/ru unknown
- 2016-09-16 BR BR112018005407A patent/BR112018005407A8/pt active Search and Examination
- 2016-09-16 EP EP16774750.0A patent/EP3350223B1/en active Active
- 2016-09-16 AR ARP160102834A patent/AR106055A1/es unknown
- 2016-09-16 MA MA052643A patent/MA52643A/fr unknown
- 2016-09-16 PE PE2018000398A patent/PE20181080A1/es unknown
- 2016-09-16 UA UAA201804192A patent/UA125284C2/uk unknown
- 2016-09-16 CA CA2997015A patent/CA2997015A1/en active Pending
- 2016-09-16 PT PT167747500T patent/PT3350223T/pt unknown
- 2016-09-16 CN CN201680053598.8A patent/CN108137693B/zh active Active
- 2016-09-16 US US15/267,213 patent/US10138296B2/en active Active
- 2016-09-16 AU AU2016323460A patent/AU2016323460B2/en active Active
- 2016-09-16 EP EP20151834.7A patent/EP3693393A1/en active Pending
- 2016-09-16 ES ES16774750T patent/ES2810751T3/es active Active
- 2016-09-16 MA MA42825A patent/MA42825B1/fr unknown
- 2016-09-16 MX MX2018003185A patent/MX2018003185A/es unknown
- 2016-09-16 IL IL257761A patent/IL257761B2/en unknown
- 2016-09-16 BR BR122021002400A patent/BR122021002400A8/pt unknown
- 2016-09-16 WO PCT/US2016/052040 patent/WO2017049024A1/en active Application Filing
- 2016-09-16 RS RS20200983A patent/RS60703B1/sr unknown
- 2016-09-16 PL PL16774750T patent/PL3350223T3/pl unknown
- 2016-09-16 JP JP2018512167A patent/JP7013366B2/ja active Active
- 2016-09-16 MD MDE20180714T patent/MD3350223T2/ro unknown
-
2018
- 2018-02-28 ZA ZA2018/01427A patent/ZA201801427B/en unknown
- 2018-03-16 CL CL2018000711A patent/CL2018000711A1/es unknown
- 2018-03-16 PH PH12018500580A patent/PH12018500580A1/en unknown
- 2018-04-09 CO CONC2018/0003736A patent/CO2018003736A2/es unknown
- 2018-08-15 HK HK18110481.5A patent/HK1251002A1/zh unknown
- 2018-10-18 US US16/164,509 patent/US11220549B2/en active Active
- 2018-11-30 HK HK18115365.5A patent/HK1256300A1/zh unknown
-
2020
- 2020-08-17 CY CY20201100767T patent/CY1123499T1/el unknown
- 2020-08-25 HR HRP20201323TT patent/HRP20201323T1/hr unknown
-
2021
- 2021-11-30 US US17/538,530 patent/US20220185902A1/en active Pending
-
2022
- 2022-01-17 JP JP2022005039A patent/JP7341259B2/ja active Active
-
2023
- 2023-06-01 AU AU2023203440A patent/AU2023203440A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201323T1 (hr) | Protutijela koja se specifično vežu na tl1a | |
| JP2018528773A5 (hr) | ||
| HRP20172004T1 (hr) | Anti-fap protutijela i postupci njihove uporabe | |
| HRP20221284T1 (hr) | Anti-pvrig antitijela i postupci uporabe | |
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
| JP2012143232A5 (hr) | ||
| HRP20150439T1 (hr) | Protutijela za humani angiopoietin 2 | |
| HRP20150776T1 (hr) | Humanizirana protutijela koja su specifiäśna za protofibrilarni oblik beta-amiloidnog peptida | |
| BR112013009376A2 (pt) | métodos para determinar isótipos de anticorpos antifármacos | |
| RU2012139181A (ru) | Стабильная композиция, содержащая антитело | |
| JP2016519124A5 (hr) | ||
| EA201000424A1 (ru) | Антитела к il-23 | |
| NZ716369A (en) | Anti-ox40 antibodies and methods of using the same | |
| WO2017193094A8 (en) | Dna monoclonal antibodies targeting checkpoint molecules | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2016539925A5 (hr) | ||
| WO2013165972A3 (en) | Anti-hepatitis b virus antibodies and use thereof | |
| JP2017510627A5 (hr) | ||
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| JP2018523110A5 (hr) | ||
| Ankerhold et al. | Circulating multimeric immune complexes drive immunopathology in COVID-19 | |
| EA201100741A1 (ru) | Антитела к модифицированным пептидам ифр-1/е человека | |
| JP2006514683A5 (hr) | ||
| WO2012017082A3 (de) | Anti-la antikörper und ihre anwendung zum immunotargeting |